As the major physiological inhibitor of plasminogen activator (PA), the type I plasminogen activator inhibitor (PAI-1) is important for controlling blood clotting and tissue remodeling events such as those that involve cell migration. The changing needs for protease activity under various physiological conditions necessitates a tight cellular control of gene expression to enable rapid changes in the levels of PAI-1 and PA activity. Cooperation between epidermal growth factor (EGF) and transforming growth factor-β (TGF-β) dramatically increase PAI-1 protein level. In this study, we found activators of tyrosine kinase (EGF, FGF, IGF-I and TNF α) or an activator of PKC (PMA) synergize with TGF- β in stimulation of PAI-1. The mechanism by which...